Research on Oral Anticancer Agents in the Contexts of Utilization, Adherence, and Health Care Delivery

NOT-CA-20-026

The purpose of this webinar was to inform potential applicants of the special interest of the National Cancer Institute (NCI) in promoting research on oral anticancer medication utilization, adherence, and health care delivery.

There are currently more than 50 U.S. FDA-approved oral anticancer agents and it is expected that the rate of development, approval, and use of these medications will continue to increase. Achieving maximal benefit of oral anticancer agents requires that they are prescribed, administered and monitored properly. Accomplishing this goal necessitates tracking utilization, identifying factors that influence adherence, and enhancing care delivery systems to support appropriate and safe use of these agents by clinicians and patients. Research studies supported by this NOSI should advance actionable knowledge regarding utilization, adherence, and/or care delivery of oral anticancer agents.